Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials

Adnan M Nagrial; Venessa T Chin; Katrin M Sjoquist; Marina Pajic; Lisa G Horvath; Andrew V Biankin; Desmond Yip

doi:10.1016/j.critrevonc.2015.07.007

Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials

Crit Rev Oncol Hematol. 2015 Dec;96(3):483-97. doi: 10.1016/j.critrevonc.2015.07.007. Epub 2015 Jul 26.

Authors

Adnan M Nagrial¹, Venessa T Chin², Katrin M Sjoquist³, Marina Pajic⁴, Lisa G Horvath⁵, Andrew V Biankin⁶, Desmond Yip⁷

Affiliations

¹ The Kinghorn Cancer Centre, 370 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia. Electronic address: a.nagrial@garvan.org.au.
² The Kinghorn Cancer Centre, 370 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia.
³ NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia; Cancer Care Centre, St. George Hospital, Kogarah, NSW, Australia.
⁴ The Kinghorn Cancer Centre, 370 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; St. Vincents's Clinical School, Faculty of Medicine, University of NSW, Australia.
⁵ The Kinghorn Cancer Centre, 370 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW 2050, Australia.
⁶ The Kinghorn Cancer Centre, 370 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; Department of Surgery, Bankstown Hospital, Eldridge Road, Bankstown, Sydney, NSW 2200, Australia; South Western Sydney Clinical School, Faculty of Medicine, University of NSW, Liverpool, NSW 2170, Australia; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow G61 1BD, Scotland, UK; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, Scotland G4 0SF, UK.
⁷ Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia; ANU Medical School, Australian National University, Acton, ACT, Australia.

PMID: 26481952
DOI: 10.1016/j.critrevonc.2015.07.007

Abstract

There remains uncertainty regarding the optimal second-line chemotherapy in advanced pancreatic ductal adenocarcinoma (PDAC). The current recommendation of 5-fluorouracil and oxaliplatin may not be relevant in current practice, as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) has become a more popular first line therapy in fit patients. The majority of studies in this setting are single-arm Phase II trials with significant heterogeneity of patient populations, treatments and outcomes. In this review, we sought to systematically review and synthesise all prospective data available for the second-line treatment of advanced PDAC.

Keywords: Chemotherapy; Pancreatic cancer; Second-line; Systematic review; Trials.

Publication types

Research Support, Non-U.S. Gov't
Review
Systematic Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Clinical Trials as Topic*
Humans
Pancreatic Neoplasms / drug therapy*
Prospective Studies
Salvage Therapy*

Abstract

Publication types

MeSH terms

Grants and funding